Cargando…

Role of ranibizumab in management of macular degeneration

Age-related macular degeneration (AMD) is one of the most common causes of severe vision loss in the western world. Both animal and human studies have established that vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of this process. Ranibizumab (Lucentis(TM), Ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Rishi P, Kaiser, Peter K
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2007
Materias:	Symposium
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2635972/ https://www.ncbi.nlm.nih.gov/pubmed/17951897

Ejemplares similares

Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration
por: Kaiser, Peter K.
Publicado: (2007)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Circulating biomarkers in glaucoma, age-related macular degeneration, and diabetic retinopathy
por: Nath, Madhu, et al.
Publicado: (2017)

Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration
por: Gopal, Lekha, et al.
Publicado: (2007)

Treatment of age-related macular degeneration: focus on ranibizumab
por: Spitzer, Martin S, et al.
Publicado: (2008)

The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration
por: Azad, Rajvardhan, et al.
Publicado: (2007)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration
por: Kim, Ramasamy
Publicado: (2007)

Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder
por: Nayyar, Rishi, et al.
Publicado: (2011)

Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration
por: Rishi, Ekta, et al.
Publicado: (2016)

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021)

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration
por: Pan, Hai-Tao, et al.
Publicado: (2020)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong, Angie HC, et al.
Publicado: (2013)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis, Nikolaos, et al.
Publicado: (2016)

A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis
por: Singh, Rishi P, et al.
Publicado: (2014)

Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration
por: Chan, Clement K., et al.
Publicado: (2023)

Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration
por: Rishi, Pukhraj, et al.
Publicado: (2011)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
por: Karagiannis, Dimitrios A, et al.
Publicado: (2009)

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration
por: Yamada, Kisaburo, et al.
Publicado: (2011)

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017)

Ranibizumab port delivery system in neovascular age-related macular degeneration
por: Chandrasekaran, Priya R., et al.
Publicado: (2022)

Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
por: Dikmetas, Ozlem, et al.
Publicado: (2022)

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
por: Rotsos, Tryfon, et al.
Publicado: (2010)

Macular Hole Formation After Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
por: Mukherjee, Chandoshi, et al.
Publicado: (2015)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration [Corrigendum]
Publicado: (2016)

A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis
por: Singh, Rishi P, et al.
Publicado: (2015)

A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)
por: Nagpal, Manish, et al.
Publicado: (2007)

Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration
por: Chen, Youxin, et al.
Publicado: (2012)

Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
por: Otsuji, Tsuyoshi, et al.
Publicado: (2013)

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
por: Chang, Yi-Sheng, et al.
Publicado: (2018)

Efficacy of ranibizumab combined with photodynamic therapy on wet age-related macular degeneration
por: Chen, Ling, et al.
Publicado: (2020)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Machine Learning to Predict Response to Ranibizumab in Neovascular Age-Related Macular Degeneration
por: Maunz, Andreas, et al.
Publicado: (2023)

Off-Label Uses of Ranibizumab and Aflibercept for Age-Related Macular Degeneration in Turkey
por: Yilmaz, Mevlut, et al.
Publicado: (2023)

Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
por: Scalzo, G C, et al.
Publicado: (2010)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova, Nadezhda P, et al.
Publicado: (2016)

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
por: Biswas, Partha, et al.
Publicado: (2011)

Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for choroidal neovascularization associated with age-related macular degeneration in an Indian patient
por: Rishi, Pukhraj, et al.
Publicado: (2008)

Management of large prostatic adenoma: Lasers versus bipolar transurethral resection of prostate
por: Gupta, Narmada P, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_oa6mb97mp39pepfnlvovm87g6n